Eye Care Surgical Ltd provides treatment and surgery for cataracts, retinal conditions, and minor eye conditions. They also offer advice and support regarding general eye health and provide medico legal services in ophthalmology.

Eye Care Surgical Ltd

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

Glaukos Corporation

Topcon focuses on solving societal challenges in healthcare, agriculture, and infrastructure with digital transformation solutions. The solutions are intended to help people around the world live better lives.

Metric
Company Name	Eye Care Surgical Ltd	Glaukos Corporation	TOPCON
Symbol		GKOS
MSH ID	COM:EYESURGERY4U	COM:GLAUKOS	COM:TOPCON:GLOBAL
Market	PRIVATE	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare	Technology
Industry	Healthcare	Medical - Devices	Technology Solutions
Country	GB	US	JP
Stage
Employee Count		907
Website	eyesurgery4u.com	glaukos.com	global.topcon.com
LinkedIn
Founders

Metric
Market Cap	6.05B	1.21B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue		314.71M
Revenue (LTM)
Revenue (NTM)
Gross Profit		239.14M
EBITDA		-82.12M
Operating Income		-128.70M
Net Income		-134.66M
EPS		-2.78
Diluted EPS		-2.78
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.77
Operating Profit Margin		-0.36
EBITDA Margin		-0.26
Net Profit Margin		-0.43
Return on Equity		-0.28
Return on Assets		-0.14
Return on Capital Employed		-0.14

EYES

COM:EYESURGERY4U

Eye Care Surgical Ltd

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-34.36
P/B Ratio		9.30
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		21.84
EV Multiple		-44.37

Metric
Days Sales Outstanding		47.28
Days Payables Outstanding		51.43
Days Inventory Outstanding		257.02
Operating Cycle		311.72
Cash Conversion Cycle		259.12
Asset Turnover		0.37

Metric
Operating Cash Flow		-57.76M
Free Cash Flow		-78.01M
Cash Flow to Debt		-0.07
Operating Cash Flow/Sales		-0.08
Free Cash Flow Yield		-0.01

Metric
Cash & Equivalents		93.47M
Accounts Receivable		-3.84M
Inventory		41.99M
Goodwill		66.13M
Debt to Capitalization		0.46
Debt to Assets		0.40
Current Ratio		5.95
Quick Ratio		4.68

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.10
R&D to Revenue		0.46
SG&A to Revenue